Sulfated polymannuroguluronate, a novel anti-acquired immune deficiency syndrome drug candidate, blocks neuroinflammatory signalling by targeting the transactivator of transcription (Tat) protein
Sulfated polymannuroguluronate (SPMG), a novel anti-acquired immune deficiency syndrome (AIDS) drug candidate, exhibits anti-apoptosis via combating oxidative damage of mitochondria in T cell.